Liminatus Pharma shares surge 14.15% intraday as clinical-stage immuno-oncology company advances IBA101, a humanized anti-CD47 monoclonal antibody for advanced solid tumors.
ByAinvest
Friday, Feb 6, 2026 9:53 am ET1min read
LIMN--
Liminatus Pharma surged 14.15% intraday, with the company announcing its lead candidate IBA101, a humanized anti-CD47 monoclonal antibody for advanced solid cancers like non-small cell lung cancer.
The company is a pre-clinical stage immuno-oncology firm focused on developing novel immunomodulatory cancer therapies, primarily targeting advanced solid tumors through its pipeline of innovative treatments.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet